MabDesign is a French association of the industrial sector of biomedicines. Created in 2014 in response to the call for projects “Filière Industriel Stratégique d’Avenir”, and in response to a proposal from the previous CSF Bioproduction, MabDesign aims to structure the industrial sector of biomedicines in France from its R&D phases to marketing, via bioproduction […]
Back to London in March 2022, Cevidra team will attend to the 8th RWE, Market Access, Pricing & Reimbursement Congress co-located with the Expanded Access Programmes Global Congress. The conferences will focus on critical issues that shape the future of European Market Access. We will meet with stakeholders from industry (government, pharmaceuticals, biotech non-profits, research […]
The Company CEVIDRA is a family-owned pharmaceutical company specializing in the marketing of high added value drugs and which wants to make innovative therapies accessible to thousands of French patients suffering from rare diseases. Cevidra offers unique and comprehensive support in BtoB and covers activities related to the operation, manufacturing, storage and distribution of products. […]
Cevidra brings in biotech expert profile to drive the advent of next-generation medicines to the French market
Cevidra brings in biotech expert profile to drive the advent of next-generation medicines to the French market We’re pleased to announce Loïc FIEVET, PharmD, PhD, will serve as a new Deputy Qualified Person of Cevidra company through its next chapter, as it aims to bring new #EarlyAccess medicines to French patients. After a first milestone in clinical trial bioproduction sites as QC manager, notably at EFS in collaboration with the CHU de Toulouse, he then advised multiple biotechnology companies as […]
Cevidra will attend to the Bio Digital Congress Benefits of a digital event Through the pandemic and the pivot to digital, ...